Retatrutide: The Triple-Action Weight Loss Drug (2026 Guide)
Retatrutide is the first drug to activate three metabolic receptors at once — GLP-1, GIP, and glucagon. Phase 3 data shows up to 28.7% body weight loss, making it the most potent obesity drug candidate ever tested. Here is everything we know about Eli Lilly's next blockbuster.
Retatrutide at a Glance
Retatrutide (LY3437943) is an investigational once-weekly injectable peptide that simultaneously activates three hormone receptors involved in metabolism: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism is what makes it fundamentally different from every obesity drug on the market or in late-stage development.
How It Works: Three Receptors, One Drug
GLP-1 Receptor
Reduces appetite, slows gastric emptying, and improves insulin secretion. This is the same mechanism used by semaglutide (Wegovy, Ozempic) and the GLP-1 component of tirzepatide (Zepbound).
GIP Receptor
Enhances insulin sensitivity, improves fat metabolism, and works synergistically with GLP-1 to amplify weight loss. This dual action (GLP-1 + GIP) is what makes tirzepatide more effective than semaglutide alone.
Glucagon Receptor
Increases energy expenditure and promotes fat burning, particularly in the liver. This is the novel third targetthat no other approved obesity drug activates — and it may explain why retatrutide's weight loss exceeds even tirzepatide.
The logic behind the triple agonist approach is additive: GLP-1 suppresses appetite and slows digestion, GIP improves metabolic efficiency and enhances the GLP-1 effect, and glucagon directly increases how many calories your body burns. Where GLP-1 drugs primarily reduce energy intake, the glucagon component adds energy expenditureto the equation. This two-pronged approach — eating less while burning more — may explain the unprecedented weight loss numbers.
There is also evidence that glucagon receptor activation specifically promotes hepatic fat reduction, which could make retatrutide particularly valuable for patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD). Phase 2 data showed significant liver fat reduction in retatrutide-treated patients.
Phase 3 Trial Results
TRIUMPH-4: Obesity + Osteoarthritis
The first Phase 3 readout came from the TRIUMPH-4 trial, which studied retatrutide in patients with obesity and knee osteoarthritis. Results announced in late 2025 were striking:
Patients on the 12mg dose lost an average of 28.7% of their body weight — more than 70 pounds on average — along with substantial improvements in osteoarthritis pain and physical function. The placebo group lost just 2.1%. The 9mg dose achieved 26.4% weight loss.
TRANSCEND-T2D-1: Type 2 Diabetes
In March 2026, Lilly announced results from the first Phase 3 trial in type 2 diabetes. Participants achieved average A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs on the highest dose. These results demonstrate that retatrutide is effective for both weight loss and blood sugar control in people with T2D.
Upcoming Phase 3 Readouts (2026)
Seven additional Phase 3 readouts are expected through 2026 across the TRIUMPH and TRANSCEND programs. These will evaluate retatrutide in broader obesity populations, additional doses (including a 4mg maintenance dose), cardiovascular outcomes, and metabolic liver disease. The full TRIUMPH program spans multiple trials designed to support a comprehensive regulatory submission.
How Retatrutide Compares to Tirzepatide and Semaglutide
| Feature | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| Receptor Targets | GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Max Weight Loss (trials) | ~28.7% | ~22.5% | ~15% |
| Dosing | Once weekly injection | Once weekly injection | Once weekly injection |
| Energy Expenditure | Yes (glucagon component) | Limited | Minimal |
| Liver Fat Reduction | Significant (Phase 2) | Moderate | Some |
| FDA Status | Phase 3 (multiple readouts 2026) | Approved | Approved |
| Expected Approval | 2027–2028 (estimated) | Available now | Available now |
Cross-trial comparisons have significant limitations. Different trial populations, durations, and endpoints make direct comparisons approximate. Only head-to-head trials can definitively compare efficacy.
Expected Timeline
Safety Data So Far
Retatrutide's safety profile across Phase 2 and early Phase 3 data is broadly consistent with the GLP-1 drug class, though the glucagon component introduces some unique considerations:
Common Side Effects (GI-related)
- Nausea — the most frequent adverse event, consistent with other GLP-1 drugs
- Diarrhea — reported more frequently than with some GLP-1-only drugs, possibly related to the glucagon component
- Vomiting — typically mild-to-moderate and decreasing over time with dose titration
- Decreased appetite — expected pharmacological effect
Glucagon-Specific Monitoring
Because glucagon raises blood sugar, there was initial concern that the glucagon component could worsen glycemic control, particularly in people with type 2 diabetes. However, Phase 3 data from TRANSCEND-T2D-1 showed the opposite: participants achieved significant A1C reductions (up to 2.0%), suggesting the GLP-1 and GIP components more than compensate for glucagon's glucose-raising effect.
Heart Rate
GLP-1 drugs are associated with small increases in resting heart rate (typically 2–4 bpm). The cardiovascular outcome trials (currently underway) will provide definitive data on retatrutide's long-term cardiovascular safety profile. Early data has not shown concerning cardiac signals.
Discontinuation Rates
In Phase 2 trials, discontinuation rates due to adverse events were higher at the highest dose (12mg) compared to lower doses, which is consistent with the broader GLP-1 class. The Phase 3 program includes a 4mg maintenance dose option, which may offer a better tolerability profile for long-term use after initial weight loss is achieved.
Who Could Retatrutide Be For?
Patients Who Need Maximum Weight Loss
With up to 28.7% body weight loss in trials, retatrutide may be appropriate for patients with severe obesity (BMI 40+) or obesity-related comorbidities who need the most aggressive pharmacological intervention available.
Metabolic Liver Disease
The glucagon component's effect on liver fat makes retatrutide a potential option for patients with MASLD/MASH. Phase 2 data showed significant liver fat reduction, and dedicated liver trials are planned.
Patients Who Plateau on Current GLP-1 Drugs
Some patients reach a weight loss plateau on semaglutide or tirzepatide. Retatrutide's additional glucagon receptor activation and higher ceiling of efficacy could offer further weight loss for these individuals.
Obesity with Osteoarthritis
The TRIUMPH-4 trial specifically showed improvements in osteoarthritis pain and physical function alongside weight loss, suggesting retatrutide could be particularly beneficial for this large patient population.
Frequently Asked Questions
When will retatrutide be available?
Retatrutide is still in Phase 3 trials with multiple readouts expected throughout 2026. Eli Lilly has not yet submitted a regulatory application. Based on the trial timeline, FDA submission could occur in late 2026 or early 2027, with potential approval in 2027-2028. It is not available for prescription today.
Is retatrutide better than Zepbound (tirzepatide)?
Phase 3 data shows retatrutide achieves higher average weight loss (~28.7%) compared to tirzepatide's trials (~22.5%). However, these are cross-trial comparisons with different patient populations. A direct head-to-head trial would be needed for definitive comparison. Retatrutide also adds the glucagon mechanism, which increases energy expenditure and liver fat reduction.
What is a triple agonist?
A triple agonist is a drug that activates three different hormone receptors simultaneously. Retatrutide activates the GLP-1, GIP, and glucagon receptors. For comparison, semaglutide (Wegovy) is a single agonist (GLP-1 only) and tirzepatide (Zepbound) is a dual agonist (GLP-1 + GIP). Each additional receptor target adds a complementary metabolic mechanism.
Will retatrutide be a pill or injection?
Retatrutide is a once-weekly subcutaneous injection, similar to Wegovy and Zepbound. There are currently no announced plans for an oral formulation. As a peptide drug, creating an oral version would require the same absorption challenges that make oral semaglutide (Rybelsus) complex.
How much weight can you lose on retatrutide?
In the TRIUMPH-4 Phase 3 trial, participants on the 12mg dose lost an average of 28.7% of their body weight (approximately 71 lbs). The 9mg dose achieved 26.4% weight loss. Individual results will vary based on starting weight, dose, diet, exercise, and other factors.
Is retatrutide safe for people with type 2 diabetes?
The TRANSCEND-T2D-1 Phase 3 trial showed that retatrutide achieved significant A1C reductions (up to 2.0%) alongside weight loss in people with type 2 diabetes. Despite the glucagon component (which can raise blood sugar), the overall effect was strongly glucose-lowering, suggesting the GLP-1 and GIP components more than compensate.
Can I get retatrutide from a compounding pharmacy?
No. Retatrutide is an investigational drug that has not been approved by the FDA. It is not legally available outside of clinical trials. Any online sellers claiming to offer retatrutide are selling unregulated, unverified products. We strongly advise against purchasing unapproved investigational drugs from any source.
Cannot Wait for Retatrutide?
Retatrutide is years from pharmacy shelves, but proven GLP-1 treatments are available today. Compare verified providers and find the right option for your weight loss goals.